Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Aikaterini F. Giannopoulou, Athanassios D. Velentzas, Eumorphia G. Konstantakou, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 6, pp. 1291-1291
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
M. Janaki Ramaiah, Anjana Devi Tangutur, M. Rajasekhar Reddy
Life Sciences (2021) Vol. 277, pp. 119504-119504
Closed Access | Times Cited: 217
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms
Fei Li, Zaosong Zheng, Wei Chen, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100938-100938
Closed Access | Times Cited: 92
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 78
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Iris Lodewijk, Sandra P. Nunes, Rui Henrique, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 59
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 18
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
Salomé Paillas, Chee Kin Then, Susan Kilgas, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 107, Iss. 1, pp. 212-221
Open Access | Times Cited: 27
LncRNA PVT1 contributes to invasion and doxorubicin resistance of bladder cancer cells through promoting MDM2 expression and AURKB‐mediated p53 ubiquitination
Xiaoqin Jiang, Huizhen Li, Fang Yu, et al.
Environmental Toxicology (2022) Vol. 37, Iss. 6, pp. 1495-1508
Closed Access | Times Cited: 17
Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring
Yuchen Zeng, Anqi Wang, Wei Lv, et al.
Clinical and Translational Discovery (2023) Vol. 3, Iss. 2
Open Access | Times Cited: 10
New Approaches to Targeting Epigenetic Regulation in Bladder Cancer
Daryl Thompson, Nathan Lawrentschuk, Damien Bolton
Cancers (2023) Vol. 15, Iss. 6, pp. 1856-1856
Open Access | Times Cited: 9
Potential clinical application of microRNAs in bladder cancer
Pei Wang, Xiaowei Wei, Xiaojun Qu, et al.
Journal of Biomedical Research (2024) Vol. 38, Iss. 4, pp. 289-289
Open Access | Times Cited: 3
Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
Saira Justin, Jochen Rutz, Sebastian Maxeiner, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 4026-4026
Open Access | Times Cited: 26
Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers
Amit Sharma, Hongde Liu, Martina C. Herwig‐Carl, et al.
Cancer Investigation (2021) Vol. 39, Iss. 3, pp. 257-273
Closed Access | Times Cited: 22
Histone Deacetylase Inhibitors from Marine Invertebrates
Claudio Luparello, Manuela Mauro, Vincenzo Arizza, et al.
Biology (2020) Vol. 9, Iss. 12, pp. 429-429
Open Access | Times Cited: 21
Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
Dimitrios Goutas, Stamatios Theocharis, Gerasimos Tsourouflis
Diagnostics (2021) Vol. 11, Iss. 8, pp. 1346-1346
Open Access | Times Cited: 19
Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives
Mohammed Ghiboub, Ahmed M I Elfiky, Menno P.J. de Winther, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 5, pp. 336-336
Open Access | Times Cited: 18
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems
Jenna Buckwalter, Wilson Chan, Lauren Shuman, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2599-2599
Open Access | Times Cited: 21
Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment
Yuxuan Song, Yiqing Du, Caipeng Qin, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 11
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
Zechen Wang, Viswanathan Muthusamy, Daniel P. Petrylak, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 6
Epigenetic and Genetic Keys to Fight HPV-Related Cancers
Veronica Folliero, Federica Dell’Annunziata, Annalisa Chianese, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5583-5583
Open Access | Times Cited: 6
Associations of sirtuins with clinicopathological variables and prognosis in human ovarian cancer
Qikuan He, Kai Chen, Ruifan Ye, et al.
Oncology Letters (2020)
Open Access | Times Cited: 17
Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro
Saira Justin, Jochen Rutz, Sebastian Maxeiner, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5582-5582
Open Access | Times Cited: 17
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
Ananda Ayyappan Jaguva Vasudevan, Michèle J. Hoffmann, Michael Leif Christian Beck, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2135-2135
Open Access | Times Cited: 17
Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives
Linda Silina, Fatlinda Maksut, Isabelle Bernard‐Pierrot, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 14
Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer
Alba Loras, Cristina Segovia, José Luis Ruiz-Cerdá
Cancers (2021) Vol. 13, Iss. 11, pp. 2719-2719
Open Access | Times Cited: 12
The Potential Role of Mitochondrial Acetaldehyde Dehydrogenase 2 in Urological Cancers From the Perspective of Ferroptosis and Cellular Senescence
Weizhen Zhu, Dechao Feng, Xu Shi, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top